Federal laboratories tested 4,534 people for Zika virus during the first nine weeks of 2016 and confirmed infection in 197, a workload that now has its first commercial outlet after regulators authorized a diagnostic made by Quest Diagnostics.

The Food and Drug Administration on Thursday granted emergency use authorization to a molecular test developed by Focus Diagnostics, a Quest subsidiary. The company said the assay is the first test from a commercial laboratory provider authorized to detect Zika viral RNA and that it expects to make testing available to physicians early next week, including in Puerto Rico.

The decision does not amount to conventional FDA approval. Emergency use authorization permits an unapproved medical product to be used during a declared emergency when specified statutory conditions are met and adequate approved alternatives are unavailable. The test is intended for certain patients whose symptoms, travel or exposure history meet federal criteria, and samples will be processed at a Quest reference laboratory in San Juan Capistrano, California.

Until now, physicians generally have had to route specimens through state and local health departments to laboratories designated by the Centers for Disease Control and Prevention. The commercial pathway could widen access as mosquito season approaches and as clinicians counsel pregnant women, the population facing the gravest known consequences of infection.

A narrow window for molecular detection

The Quest assay uses real-time reverse transcription polymerase chain reaction, or rRT-PCR, to look for genetic material from the virus in serum. A positive result establishes that Zika RNA is present. But the method is most useful early in infection because viral material in blood can disappear quickly, leaving a negative result that does not necessarily exclude earlier exposure.

That limitation makes timing and patient selection central to the test’s value. In its March laboratory guidance, the World Health Organization advised laboratories to interpret molecular and antibody results alongside the date of symptom onset, vaccination history, exposure and local circulation of related flaviviruses such as dengue. Cross-reaction among those viruses can complicate antibody testing, while molecular testing can miss patients after the brief period when RNA is detectable.

Quest said its proprietary test is designed for qualitative detection—reporting whether viral RNA is found, not how much is present. The company will perform the assay only on specimens referred by physicians; it is not a consumer test and is not intended for screening without clinical and epidemiological justification. Reuters reported Thursday that the authorization gives doctors a direct commercial option after months in which access depended heavily on public-health channels.

Public laboratories have carried the first surge

The scale and composition of early U.S. testing show why capacity matters. A CDC analysis released April 15 found that 3,335 of the 4,534 people tested from January 3 through March 5 were pregnant women. Overall, 197 people, or 4.3 percent, had confirmed infection; another 55 had evidence of a recent flavivirus infection that could not be specified.

The yield varied sharply with symptoms. Among 1,541 people reporting at least one symptom associated with Zika, 182—11.8 percent—had confirmed infection. Only seven of 2,557 asymptomatic people tested positive. Among pregnant women, 28 of 3,335 had confirmed infection, including seven among 2,425 who reported no symptoms.

Those numbers do not measure national prevalence. They describe a selected population referred under testing criteria, heavily weighted toward pregnant travelers and others with known or possible exposure. But they demonstrate the demands placed on designated laboratories and the clinical stakes of returning answers promptly.

Federal officials had already expanded the public system in February. After the FDA authorized the CDC’s antibody assay, the agency said it would distribute the test to qualified laboratories to bolster domestic testing capacity. A subsequent Federal Register notice described the emergency authorization for the CDC Zika MAC-ELISA, which can detect an immune response but may require additional neutralization testing because of cross-reactivity.

Pregnancy drives the clinical urgency

The commercial authorization arrives as evidence has hardened that infection during pregnancy can cause microcephaly and other severe fetal brain abnormalities. Yet determining who should be tested, and when, remains a moving clinical judgment rather than a simple mass-screening program.

In guidance published March 25, the CDC recommended molecular testing for symptomatic pregnant women within the appropriate interval after symptoms or exposure, followed by antibody testing when indicated. The same interim guidance for women of reproductive age cautioned that testing was not recommended for a pregnant woman whose only possible exposure was sex with an asymptomatic partner, reflecting both limits on laboratory capacity and uncertainty in interpreting results.

Infants present a separate diagnostic challenge. CDC guidance recommends testing babies born with microcephaly or intracranial calcifications when their mothers lived in or traveled to an area of transmission, as well as infants whose mothers had positive or inconclusive results. The agency’s evaluation framework for possibly affected infants calls for additional clinical assessment and follow-up when laboratory evidence suggests congenital infection.

The Quest authorization does not eliminate those complexities. It adds a route for molecular testing, but physicians must still decide whether a patient meets the criteria, collect a specimen within a useful window and interpret a negative result in the context of exposure and symptoms.

Commercial access changes the bottleneck, not the science

Quest operates a national network of laboratories and physician relationships, making its entry important even though the authorized assay will initially be performed at a single reference facility. The company said health plans would determine coverage and patient cost, leaving reimbursement as a possible barrier even after logistical access improves.

The University of Minnesota’s Center for Infectious Disease Research and Policy noted that Quest expects to offer the molecular test broadly next week and may add serologic testing if regulators authorize appropriate antibody kits. Its April 29 assessment emphasized that the new assay is the first commercial-provider test to enter a system previously centered on CDC-authorized laboratories.

For public-health departments, shifting some physician-ordered tests to a commercial laboratory could preserve state capacity for surveillance, outbreak investigation and complex cases. For clinicians, it may simplify ordering and specimen transport. For patients, particularly pregnant women awaiting decisions about monitoring and care, the practical measure will be whether results arrive sooner without sacrificing accuracy.

The authorization is therefore a capacity milestone rather than a definitive solution. Zika diagnosis still depends on when a specimen is taken, which test is used and how results are reconciled with travel, symptoms and pregnancy. The commercial network can widen the doorway, but the underlying diagnostic uncertainty remains.